PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Brenipatide

Drugs in development · updated 30 October 2026

Brenipatide: clinical trials and development status

Name declared in trialsNot approved in the USNo EMA authorisationEstimated launch Apr 2029 – Feb 2030 (Phuturdex estimate)

As of 30 October 2026 Brenipatide is in 9 active clinical trials (recruiting or ongoing, phases I–III) for 15 diseases. The most advanced phase is III.

9Active trials
IIIMost advanced phase
15Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Brenipatide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
DepressionIII2NCT07775300
Depressive disorderIII2NCT07775300
Major depressive disorderIII2NCT07775300
Mood disorderIII2NCT07775300
AsthmaII1NCT07219173
Bipolar disorderII1NCT07286175
Chronic bronchitisII1NCT07759245
Chronic obstructive pulmonary diseaseII1NCT07759245
EmphysemaII1NCT07759245
Lung diseaseII1NCT07759245
Opioid-related disordersII1NCT07420283
SchizophreniaII1NCT07410507
SmokingII1NCT07223840
ObesityI1NCT07476118
OverweightI1NCT07476118

Everything on Brenipatide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch